SOPHiA GENETICS SA (NASDAQ:SOPH – Get Free Report) insider Philippe Menu sold 5,000 shares of the firm’s stock in a transaction on Monday, October 12th. The shares were sold at an average price of $7.26, for a total value of $36,300.00. Following the transaction, the insider directly owned 195,993 shares of the company’s stock, valued at $1,422,909.18. This represents a 2.49% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Philippe Menu also recently made the following trade(s):
- On Monday, October 5th, Philippe Menu sold 7,394 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $8.13, for a total transaction of $60,113.22.
- On Tuesday, August 25th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $8.68, for a total transaction of $43,400.00.
- On Wednesday, August 12th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $7.52, for a total transaction of $37,600.00.
- On Monday, July 27th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.66, for a total transaction of $28,300.00.
SOPHiA GENETICS Trading Down 0.4%
Shares of NASDAQ SOPH opened at $7.06 on Thursday. SOPHiA GENETICS SA has a 1 year low of $3.75 and a 1 year high of $8.98. The stock has a market cap of $592.26 million, a P/E ratio of -6.14 and a beta of 0.95. The firm has a 50-day moving average of $7.97 and a 200 day moving average of $6.22. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.69 and a quick ratio of 2.55.
Institutional Inflows and Outflows
Hedge funds have recently made changes to their positions in the stock. AWM Investment Company Inc. bought a new position in SOPHiA GENETICS during the second quarter valued at approximately $9,809,000. Principal Financial Group Inc. boosted its holdings in SOPHiA GENETICS by 0.7% in the first quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock worth $6,976,000 after purchasing an additional 9,800 shares during the last quarter. Hodges Capital Management Inc. purchased a new stake in SOPHiA GENETICS in the first quarter worth approximately $2,157,000. Sei Investments Co. bought a new stake in SOPHiA GENETICS in the 1st quarter worth approximately $1,772,000. Finally, 1492 Capital Management LLC grew its position in SOPHiA GENETICS by 8.4% in the 1st quarter. 1492 Capital Management LLC now owns 225,751 shares of the company’s stock worth $1,117,000 after purchasing an additional 17,406 shares during the period. 31.59% of the stock is owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
Several analysts recently weighed in on SOPH shares. BTIG Research upped their price target on SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. HC Wainwright reiterated a “buy” rating and set a $14.00 price objective on shares of SOPHiA GENETICS in a research note on Monday. Zacks Research raised SOPHiA GENETICS to a “hold” rating in a report on Tuesday, July 21st. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Friday, July 17th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, SOPHiA GENETICS has a consensus rating of “Hold” and a consensus price target of $10.00.
Read Our Latest Analysis on SOPH
About SOPHiA GENETICS
SOPHiA GENETICS is a healthcare technology company that develops cloud-based data analytics solutions for the life sciences and healthcare industries. Its platform is designed to help organizations analyze and interpret complex genomic and multimodal data to support more informed clinical and research decisions.
The company’s principal offering, the SOPHiA DDM platform, combines data management, analytics and artificial intelligence capabilities. It supports applications including cancer genomics, hereditary disease analysis, reproductive health and other areas of precision medicine.
Featured Stories
- Five stocks we like better than SOPHiA GENETICS
- Tesla Wants to Make Its Own Chips—What Could Go Wrong?
- IREN Limited’s AI Pivot Gains Traction—But Can Its Data Centers Deliver?
- PBF Energy’s Stunning Rally Faces a Critical Test
- Citi Stock Falls Despite Earnings Beat: What Investors Need to Know
Receive News & Ratings for SOPHiA GENETICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SOPHiA GENETICS and related companies with MarketBeat.com's FREE daily email newsletter.
